Rising disposable incomes, growing recognition of diabetes-related risks, and government efforts to enhance chronic disease management are expected to support substantial market growth for GLP-1 receptor agonists across Asia Pacific
Abrahamsen RK, Lund AM, Rasmussen J
Betting on a widespread GLP-1 adoption, some private equity investors are practicing an investor version of the Ozempic diet and are refraining from investing in consumer companies (such as snackmakers, alcohol brands, or restaurant chains) that could be negatively impacted by the GLP-1 boom, believing that profits will get squeezed as GLP-1 users no longer crave them and/or obesity rates fall
What the data means and what you can buy now
doi:10.3945/ajcn.116.148585
Patients seeking care from a trusted TRT clinic in Dallas can work with our experienced providers to develop personalized wellness plans that align with their health goals